A McGill University research team has identified a key mechanism that drives neuroendocrine prostate cancer — a rare, aggressive, and treatment-resistant form of the disease — and discovered a dual-drug approach that slows tumour growth in preclinical models. Published in Genes & Development, the study shows that loss of the protein ERRγ accelerates cancer progression, while targeting the overactive genes that take over in its absence significantly reduces tumour growth. The findings point to ERRγ as a promising new therapeutic target and offer hope for patients with few existing treatment options. The post New therapeutic strategies show promise against a hard-to-treat prostate cancer appeared first on Hospital News.